
PRECISION BIOSC. O.N.
Share · US74019P2074 · DTIL · A400AS (XNCM)
4,66 EUR
09.06.2025 19:59
Current Prices from PRECISION BIOSC. O.N.
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
DTIL
|
USD
|
09.06.2025 19:59
|
5,31 USD
| 5,39 USD
-1,45 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | 3,68 % | 0,30 % | -1,49 % | -17,78 % | -59,01 % | -97,95 % |
Company Profile for PRECISION BIOSC. O.N. Share
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Company Data
Name PRECISION BIOSC. O.N.
Company Precision BioSciences, Inc.
Symbol DTIL
Primary Exchange
Frankfurt

WKN A400AS
ISIN US74019P2074
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael Amoroso
Market Capitalization 53 Mio
Country United States of America
Currency EUR
Employees 0,1 T
Address 302 East Pettigrew Street, 27701 Durham
IPO Date 2019-03-28
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | PBS0.F |
NASDAQ | DTIL |
More Shares
Investors who PRECISION BIOSC. O.N. hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.